UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Raises Stake in Bio-Rad Laboratories, Inc. (NYSE:BIO)

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its holdings in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO - Free Report) by 1.0% during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 441,098 shares of the medical research company's stock after buying an additional 4,260 shares during the quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned 1.58% of Bio-Rad Laboratories worth $147,583,000 as of its most recent SEC filing.

A number of other hedge funds also recently added to or reduced their stakes in the business. Capital Advisors Ltd. LLC raised its holdings in shares of Bio-Rad Laboratories by 193.8% in the 2nd quarter. Capital Advisors Ltd. LLC now owns 94 shares of the medical research company's stock valued at $26,000 after purchasing an additional 62 shares in the last quarter. UMB Bank n.a. raised its holdings in shares of Bio-Rad Laboratories by 140.6% in the 3rd quarter. UMB Bank n.a. now owns 77 shares of the medical research company's stock valued at $26,000 after purchasing an additional 45 shares in the last quarter. Gladius Capital Management LP acquired a new stake in shares of Bio-Rad Laboratories in the 3rd quarter valued at $32,000. Headlands Technologies LLC acquired a new stake in shares of Bio-Rad Laboratories in the 2nd quarter valued at $51,000. Finally, Quarry LP acquired a new stake in shares of Bio-Rad Laboratories in the 2nd quarter valued at $59,000. 65.24% of the stock is currently owned by institutional investors and hedge funds.

Bio-Rad Laboratories Stock Performance

Bio-Rad Laboratories stock traded up $2.05 during midday trading on Friday, hitting $340.53. 78,237 shares of the company's stock were exchanged, compared to its average volume of 197,129. Bio-Rad Laboratories, Inc. has a 12-month low of $262.12 and a 12-month high of $387.99. The company has a debt-to-equity ratio of 0.16, a quick ratio of 4.52 and a current ratio of 6.14. The stock has a market cap of $9.53 billion, a price-to-earnings ratio of -12.46 and a beta of 0.93. The firm's 50 day simple moving average is $340.77 and its 200 day simple moving average is $317.92.

Bio-Rad Laboratories (NYSE:BIO - Get Free Report) last issued its quarterly earnings data on Wednesday, October 30th. The medical research company reported $2.01 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.16 by $0.85. Bio-Rad Laboratories had a negative net margin of 30.18% and a positive return on equity of 3.74%. The company had revenue of $649.70 million for the quarter, compared to the consensus estimate of $628.18 million. During the same period last year, the firm posted $2.33 EPS. Bio-Rad Laboratories's revenue for the quarter was up 2.8% on a year-over-year basis. Equities research analysts predict that Bio-Rad Laboratories, Inc. will post 10.29 EPS for the current year.

Insider Transactions at Bio-Rad Laboratories

In other news, COO Andrew J. Last sold 3,000 shares of the firm's stock in a transaction on Friday, September 6th. The shares were sold at an average price of $329.94, for a total value of $989,820.00. Following the completion of the sale, the chief operating officer now owns 7,559 shares in the company, valued at approximately $2,494,016.46. This trade represents a 28.41 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP James Barry sold 623 shares of the firm's stock in a transaction on Wednesday, September 4th. The stock was sold at an average price of $330.49, for a total transaction of $205,895.27. Following the completion of the sale, the executive vice president now owns 147 shares of the company's stock, valued at $48,582.03. This trade represents a 80.91 % decrease in their position. The disclosure for this sale can be found here. Company insiders own 17.06% of the company's stock.

Analyst Ratings Changes

A number of research analysts recently commented on the stock. Royal Bank of Canada increased their target price on shares of Bio-Rad Laboratories from $446.00 to $469.00 and gave the company an "outperform" rating in a research report on Thursday, October 31st. StockNews.com raised shares of Bio-Rad Laboratories from a "hold" rating to a "buy" rating in a research report on Friday, November 1st. Citigroup increased their target price on shares of Bio-Rad Laboratories from $400.00 to $450.00 and gave the company a "buy" rating in a research report on Thursday, October 31st. Finally, Wells Fargo & Company assumed coverage on shares of Bio-Rad Laboratories in a research report on Tuesday, August 27th. They issued an "equal weight" rating and a $340.00 target price on the stock. Two investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company's stock. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average price target of $391.80.

Bio-Rad Laboratories Company Profile

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.